发明申请
US20110281302A1 COMPOSITIONS AND METHODS OF TREATING DISEASE WITH FGFR FUSION PROTEINS
有权
用FGFR融合蛋白治疗疾病的组合物和方法
- 专利标题: COMPOSITIONS AND METHODS OF TREATING DISEASE WITH FGFR FUSION PROTEINS
- 专利标题(中): 用FGFR融合蛋白治疗疾病的组合物和方法
-
申请号: US13157712申请日: 2011-06-10
-
公开(公告)号: US20110281302A1公开(公告)日: 2011-11-17
- 发明人: Lewis T. WILLIAMS , Elizabeth Bosch , Stephen Doberstein , Kevin Hestir , Diane Hollenbaugh , Ernestine Lee , Minmin Qin , Ali Sadra , Justin Wong , Ge Wu , Hongbing Zhang
- 申请人: Lewis T. WILLIAMS , Elizabeth Bosch , Stephen Doberstein , Kevin Hestir , Diane Hollenbaugh , Ernestine Lee , Minmin Qin , Ali Sadra , Justin Wong , Ge Wu , Hongbing Zhang
- 专利权人: Five Prime Therapeutics, Inc.
- 当前专利权人: Five Prime Therapeutics, Inc.
- 主分类号: C12P21/04
- IPC分类号: C12P21/04 ; C12N5/10 ; C07H21/04 ; C07K14/00 ; C07K16/46
摘要:
The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their stability. These fusion proteins inhibit the growth and viability of cancer cells in vitro and in vivo. The combination of the relatively high affinity of these receptors for their ligand FGFs and the demonstrated ability of these decoy receptors to inhibit tumor growth is an indication of the clinical value of the compositions and methods provided herein.